Full-Time

Associate – Global Regulatory Sciences Rotational Program

Posted on 2/20/2025

Pfizer

Pfizer

10,001+ employees

Develops and manufactures biopharmaceutical products

Social Impact
Biotechnology
Healthcare

Compensation Overview

$62.7k - $104.5kAnnually

+ Bonus

Entry, Junior

No H1B Sponsorship

Cambridge, MA, USA + 5 more

More locations: Andover, MA, USA | New City, NY, USA | Phoenixville, PA, USA | Groton, CT, USA | New York, NY, USA

Hybrid position requiring 2.5 days a week onsite.

Category
Risk & Compliance
Legal & Compliance

You match the following Pfizer's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s Degree required
  • Master’s Degree preferred
  • No more than 2 years full-time continuous work experience in a business/corporate environment
  • Career aspiration in regulatory sciences
  • Team oriented
  • Change agile; must take action on projects quickly
  • Excellent oral and written communication skills with the ability to communicate complex information and analyses to a variety of scientific audiences in both verbal and written format, including to senior management
  • Excellent analytic and problem-solving skills
  • Presentation skills - Is effective in a variety of formal presentation settings; one-on-one, small and large groups, with peers, direct reports and senior managers
  • Negotiation skills - Can negotiate skillfully and diplomatically in tough situations with both internal and external groups. Gains trust quickly of other parties to the negotiations
Responsibilities
  • Work across GRS functions supporting key regulatory tasks and deliverables across programs, disease areas, and region(s) for global regulatory sciences
  • Be accountable for timely planning, preparation, submissions and approvals of program(s) deliverables in the designated region
  • Be accountable for ensuring optimal regulatory interactions with Health Authorities in relation to the assigned project(s) within designated region
  • Role can be combined with other GRS function activities based upon priorities
  • Project(s) assigned can be in early development/registration and/or at post-authorization stage across categories
  • Partners with project teams and other customer groups (e.g. RU/BU, Commercial Teams) to ensure required regulatory contributions meet business needs and are provided to the project teams, to agreed time and quality standards
  • Ensures regulatory contributions achieve the objectives in the strategy, achieve agreed standards, maximizing overall project delivery time and probability of success and facilitating post filing activities

Pfizer is a biopharmaceutical company that focuses on creating and manufacturing healthcare products, including medicines and vaccines. The company conducts extensive research and development to discover new treatments, which are then commercialized and sold to various clients such as governments, healthcare providers, and patients. Pfizer's products include vaccines, oncology treatments, and specialized medicines, with a notable contribution to the COVID-19 pandemic through its partnership with BioNTech to develop a widely used vaccine. What sets Pfizer apart from its competitors is its strong commitment to public health, exemplified by initiatives to provide vaccines to underserved populations and a continuous effort to expand its product portfolio with new approvals. The company's goal is to improve global health by ensuring access to effective treatments and vaccines.

Company Size

10,001+

Company Stage

IPO

Total Funding

$3.8B

Headquarters

New York City, New York

Founded

1849

Simplify Jobs

Simplify's Take

What believers are saying

  • Starboard Value's $1 billion stake may drive strategic changes and increase shareholder value.
  • Pfizer's investment in fibrosis treatments expands its therapeutic areas.
  • Involvement in protein modification research diversifies Pfizer's treatment offerings.

What critics are saying

  • Slowdown in COVID-19 vaccine demand impacts Pfizer's revenue streams.
  • Activist investor Starboard Value may influence Pfizer's strategic decisions.
  • Emerging biotech companies pose a threat to Pfizer's market share in immunotherapy.

What makes Pfizer unique

  • Pfizer's partnership with BioNTech led to a highly effective COVID-19 vaccine.
  • Pfizer invests in AI disease models, enhancing predictive insights for drug development.
  • Pfizer's oncology portfolio is strengthened by investments in TCR-based immunotherapies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Company News

Business Wire
Jan 16th, 2025
Normunity Closes $75 Million Series B Financing to Advance Lead Drug Program Into the Clinic and Broaden Pipeline of Novel Anti-Cancer Therapies Targeting Untapped Drug Mechanisms

Normunity, a biotechnology company creating novel anti-cancer therapies, today announced that it has closed a Series B financing for $75 million. The

TechCrunch
Oct 23rd, 2024
Promise Bio exits stealth backed by Pfizer and AstraZeneca | TechCrunch

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune diseases.

The Wall Street Journal
Oct 7th, 2024
Exclusive | Activist Starboard Value Takes $1 Billion Stake in Pfizer

The drugmaker’s shares have slumped as demand for Covid-19 vaccines and treatments had slowed.

Benzinga
Oct 3rd, 2024
Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health InvestorsEnara Bio's EDAPT® platform is

Business Wire
Jul 18th, 2024
CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

CytoReason, a leader in developing computational disease models for predictive insights, announced today it secured an aggregated $80 million from Our